Clinical impact of using chemoradiotherapy as a primary treatment for hypopharyngeal cancer

Acta Otolaryngol Suppl. 2002:(547):11-4. doi: 10.1080/000164802760057491.

Abstract

Eighty-eight patients with hypopharyngeal cancer who received chemoradiotherapy as the primary treatment between 1979 and 1997 were investigated. Forty-six patients who received surgery as the primary treatment were analyzed as a control group. There were no statistically significant differences regarding TN classification, tumor stage, tumor site, age or sex between the radiation and surgery groups. The 5-year cumulative survival rate of primary chemoradiotherapy was 47% and this did not differ significantly from that for the primary surgery group. The larynx was preserved in 74% of cases in the primary chemoradiotherapy group, a far better preservation rate than that in the surgery group. After primary chemoradiotherapy, complete remission (CR) was observed in 59% of cases and the average period of CR was 38 months. Among patients with residual tumor, a salvage operation was employed in 31 cases, 13 patients refused to receive surgery and 8 were inoperable. A salvage operation was performed in 35% of all cases and the 5-year cumulative survival rate was 50%. Based on the 5-year survival, primary CR, salvage and laryngeal preservation rates, we conclude that chemoradiotherapy is a good primary treatment for hypopharyngeal cancer.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Antimetabolites, Antineoplastic / administration & dosage
  • Antimetabolites, Antineoplastic / therapeutic use*
  • Chemotherapy, Adjuvant
  • Cisplatin / administration & dosage
  • Cisplatin / therapeutic use*
  • Drug Therapy, Combination
  • Female
  • Follow-Up Studies
  • Humans
  • Hypopharyngeal Neoplasms / drug therapy*
  • Hypopharyngeal Neoplasms / mortality
  • Hypopharyngeal Neoplasms / radiotherapy*
  • Male
  • Outcome Assessment, Health Care
  • Pharynx / drug effects
  • Pharynx / radiation effects
  • Radiation-Sensitizing Agents / administration & dosage
  • Radiation-Sensitizing Agents / therapeutic use*
  • Radiotherapy Dosage
  • Survival Rate
  • Tegafur / administration & dosage
  • Tegafur / therapeutic use*
  • Time Factors
  • Uracil / administration & dosage
  • Uracil / therapeutic use*

Substances

  • Antimetabolites, Antineoplastic
  • Radiation-Sensitizing Agents
  • Tegafur
  • Uracil
  • Cisplatin